We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Microfluidic Chip Containing Antibody-Coated Nanoparticles Improves Cancer Detection

By LabMedica International staff writers
Posted on 11 Feb 2010
A highly sensitive method for detecting cancer can detect single molecules of compounds in blood that signify specific types of tumor.

The technology is based on a microfluidic chip with tiny channels into which a blood sample is drawn. More...
Specially sensitized nanoparticles in the channels capture marker proteins in the blood that indicate certain types of cancer.

The Fraunhofer Institute for Silicate Research (ISR; Wurzburg, Germany) is developing the new diagnostic method to detect cancer in its initial stages so that treatment can start early and improve the patient's chance of recovery. The method should improve cancer detection 100-fold.

Similar testing systems already exist but their measurements are not sufficiently precise, and they can only detect molecules when present in the blood in large quantities. These tests, which must be carried out in a laboratory, are also time-consuming and costly.

Dr Jörn Probst, head of the business unit life science at the ISC explained, "We have placed antibody-occupied nanoparticles on the sensor electrode which 'fish' out the relevant proteins. For this purpose, we repeatedly pump the blood across the electrode surface. As with a river, the flow is fastest in mid-channel and the water runs more slowly near the bank. We have therefore made a sort of fishing rod using nanoparticles which registers the antibodies in the middle of the blood flow where most proteins swim by per unit of time." If an antibody catches the matching protein that indicates a tumor, the electrical charge distribution shifts and this is picked up by the electrode.

The ISC groups are developing a first demonstrator combining four independent single-molecule-sensitive biosensors. They are also working on the simultaneous detection of several tumor markers, which will increase the clarity of tests.

Related Links:

Fraunhofer Institute for Silicate Research





Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Clinical Informatics Platform
CLARION™
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.